ALLOPURINOL
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK ·+4
RANBAXY/SUN PHA
Drug class
Hyperuricemia Agents (non-uricosuric)
Hyperuricemia Agents (non-uricosuric) is a clinical and compendial classification grouping medications that reduce serum uric acid concentrations through mechanisms other than increasing renal uric acid clearance. Read more about Hyperuricemia Agents (non-uricosuric)
58 drugs in this class 52 manufacturers
Drugs in Hyperuricemia Agents (non-uricosuric)
ALLOPURINOL
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK ·+4
ZYDUS PHARMACEU
ZYLOPRIM (allopurinol)
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK ·+4
CASPER PHARMA L
ALLOPURINOL SODIUM
HYPERURICEMIA AGENTS (NON-URICOSURIC) · HYPERURICEMIA DUE TO CANCER THERAPY
Hikma Pharmaceuticals USA
ALLOPURINOL
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK ·+4
UNICHEM PHARMAC
FEBUXOSTAT
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK
SUN PHARMA GLOB
FEBUXOSTAT
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK
ALEMBIC PHARMAC
FEBUXOSTAT
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK
Hikma Pharmaceuticals USA
KRYSTEXXA (pegloticase)
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK
HORIZON/AMGEN
Filter & compare in the drug finder →
Opens the drug finder with Hyperuricemia Agents (non-uricosuric) preselected. Add indication or manufacturer filters there.
Hyperuricemia Agents (non-uricosuric) is a clinical and compendial classification grouping medications that reduce serum uric acid concentrations through mechanisms other than increasing renal uric acid clearance.
Rather than promoting urinary excretion via renal transporter inhibition, these agents primarily function by inhibiting uric acid synthesis through xanthine oxidase inhibition or by enzymatically degrading existing circulating urate into soluble allantoin.
The class is therapeutically utilized in the management and prevention of chronic gout, hyperuricemia associated with cancer chemotherapy or tumor lysis syndrome, and recurrent calcium oxalate nephrolithiasis secondary to hyperuricosuria.
-
fda.gov
Hyperuricemia Agents (non-uricosuric) is a clinical and compendial classification grouping medications that reduce serum uric acid concentrations through mechanisms other than increasing renal uric acid clearance The class is therapeutically utilized in the management and prevention of chronic gout, hyperuricemia associated with cancer chemotherapy or tumor lysis syndrome, and recurrent calcium oxalate nephrolithiasis secondary to hyperuricosuria
-
fda.gov
Hyperuricemia Agents (non-uricosuric) is a clinical and compendial classification grouping medications that reduce serum uric acid concentrations through mechanisms other than increasing renal uric acid clearance Rather than promoting urinary excretion via renal transporter inhibition, these agents primarily function by inhibiting uric acid synthesis through xanthine oxidase inhibition or by enzymatically degrading existing circulating urate into soluble allantoin
-
connectrx.com
Hyperuricemia Agents (non-uricosuric) is a clinical and compendial classification grouping medications that reduce serum uric acid concentrations through mechanisms other than increasing renal uric acid clearance
-
singlecare.com
Rather than promoting urinary excretion via renal transporter inhibition, these agents primarily function by inhibiting uric acid synthesis through xanthine oxidase inhibition or by enzymatically degrading existing circulating urate into soluble allantoin
-
connectrx.com
Rather than promoting urinary excretion via renal transporter inhibition, these agents primarily function by inhibiting uric acid synthesis through xanthine oxidase inhibition or by enzymatically degrading existing circulating urate into soluble allantoin
-
fda.gov
The class is therapeutically utilized in the management and prevention of chronic gout, hyperuricemia associated with cancer chemotherapy or tumor lysis syndrome, and recurrent calcium oxalate nephrolithiasis secondary to hyperuricosuria
-
drugs.com
The class is therapeutically utilized in the management and prevention of chronic gout, hyperuricemia associated with cancer chemotherapy or tumor lysis syndrome, and recurrent calcium oxalate nephrolithiasis secondary to hyperuricosuria
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.